12 completed, 4 terminated, 2 unknown. 18 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 12, Terminated 4, Unknown 2 |
| Phase 1 | 3 | Completed 2, Unknown 1 |
| Phase 3 | 2 | Completed 2 |
Follow Pemphigoid, Bullous: new trials by email Literature Review of Pemphigoid, Bullous trials Research Report on Pemphigoid, Bullous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. Single Dose, Double Dose - Chronic Conjunctivitis, Stevens-Johnson Syndrome | Phase 1 / Phase 2 | Unknown | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 20 | 2022-11-11 | 2024-07-08 |
| A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid efgartigimod PH20 SC, placebo, Prednisone - Bullous Pemphigoid | Phase 2 / Phase 3 | Completed | argenx | 98 | 2022-06-09 | 2025-10-23 |
| A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid dupilumab, Matching Placebo, Oral corticosteroids (OCS) - Bullous Pemphigoid | Phase 2 / Phase 3 | Completed | Regeneron Pharmaceuticals | 106 | 2020-10-28 | 2026-06-18 |
| Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody Avdoralimab (IPH5401), Control - Bullous Pemphigoid | Phase 2 | Completed | Centre Hospitalier Universitaire de Nice | 15 | 2020-10-10 | 2026-03-24 |
| Efficacy and Safety of Ustekinumab in Bullous Pemphigoid Ustekinumab - Bullous Pemphigoid | Phase 2 | Completed | CHU de Reims | 18 | 2020-03-11 | 2023-08-08 |
| A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid Mometasone furoate, AKST4290, Placebo - Pemphigoid, Bullous | Phase 2 | Terminated | Alkahest, Inc. | 6 | 2020-01-30 | 2023-09-14 |
| rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects rVA576 - Bullous Pemphigoid (BP) | Phase 2 | Completed | AKARI Therapeutics | 9 | 2018-09-25 | 2025-04-22 |
| A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid AC-203 1% Topical Ointment, Clobetasol 0.05% Topical Ointment - Bullous Pemphigoid | Phase 2 | Terminated | TWi Biotechnology, Inc. | 10 | 2017-09-05 | 2019-09-19 |
| Ixekizumab in the Treatment of Bullous Pemphigoid Ixekizumab - Bullous Pemphigoid, Pemphigoid | Phase 2 | Completed | Mayo Clinic | 4 | 2017-08-15 | 2020-05-21 |
| Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid Bertilimumab - Pemphigoid, Bullous | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 11 | 2016-02-29 | 2025-11-26 |
| Anti-IL-5 Therapy in Bullous Pemphigoid (BP) Mepolizumab (a-IL-5 antibody), Placebo - Pemphigoid, Bullous | Phase 2 | Completed | Insel Gruppe AG, University Hospital Bern | 32 | 2013-02-13 | 2017-02-28 |
| Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment QGE031, Placebo - Bullous Pemphigoid | Phase 2 | Terminated | Novartis Pharmaceuticals | 20 | 2013-01-01 | 2016-04-28 |
| Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid DF2156A - Bullous Pemphigoid | Phase 2 | Terminated | Dompé Farmaceutici S.p.A | 4 | 2012-02-20 | 2023-12-22 |
| Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids. NPB-01, Placebo - Bullous Pemphigoid | Phase 2 | Completed | Nihon Pharmaceutical Co., Ltd | 20 | 2008-11-01 | 2010-10-25 |
| Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid leflunomide - Bullous Pemphigoid | Phase 2 | Unknown | University Hospital, Limoges | 54 | 2007-09-01 | 2008-12-04 |
| Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid Rituximab - Ocular Cicatricial Pemphigoid | Phase 1 / Phase 2 | Completed | University of Alabama at Birmingham | 3 | 2006-01-01 | 2026-05-04 |
| Rituximab in the Treatment of Patients With Bullous Pemphigoid Rituximab - Bullous Pemphigoid | Phase 1 / Phase 2 | Completed | Duke University | 8 | 2005-03-01 | 2013-04-11 |
| Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid Azathioprine or Mycophenolate mofetil - Bullous Pemphigoid | Phase 2 | Completed | University Hospital Muenster | 70 | 1997-10-01 | 2007-02-05 |
Skin Diseases (2) · Autoimmune Diseases (1) · Blindness (1) · Blister (1) · Pemphigoid, Benign Mucous Membrane (1) · Stevens-Johnson Syndrome (1)
Immune System Diseases (18) · Skin Diseases, Vesiculobullous (18) · Skin and Connective Tissue Diseases (18) · Autoimmune Diseases (17) · Skin Diseases (16) · Pathological Conditions, Signs and Symptoms (2) · Chemically-Induced Disorders (1) · Conjunctival Diseases (1) · Dermatitis (1) · Drug Eruptions (1) · Drug Hypersensitivity (1) · Drug-Related Side Effects and Adverse Reactions (1) · Erythema (1) · Erythema Multiforme (1) · Eye Diseases (1)
Rituximab (2) · 2'-((4'-trifluoromethanesulfonyloxy)phenyl)-N-methanesulfonylpropionamide (1) · Adrenal Cortex Hormones (1) · Azathioprine (1) · Clobetasol (1) · Leflunomide (1) · Mometasone Furoate (1) · Mycophenolic Acid (1) · Ointments (1) · Prednisone (1) · Ustekinumab (1) · avdoralimab (1) · diacerein (1) · dupilumab (1) · ixekizumab (1)
AKARI Therapeutics (1) · Alexion Pharmaceuticals, Inc. (1) · Alkahest, Inc. (1) · CHU de Reims (1) · Centre Hospitalier Universitaire de Nice (1) · Dompé Farmaceutici S.p.A (1) · Duke University (1) · Insel Gruppe AG, University Hospital Bern (1) · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (1) · Mayo Clinic (1) · Nihon Pharmaceutical Co., Ltd (1) · Novartis Pharmaceuticals (1) · Regeneron Pharmaceuticals (1) · TWi Biotechnology, Inc. (1) · University Hospital Muenster (1)
Germany (7) · United States (7) · France (6) · Japan (4) · Israel (3) · Spain (3) · Taiwan (3) · Australia (2) · Italy (2) · Netherlands (2) · Poland (2) · Austria (1) · Bulgaria (1) · China (1) · Croatia (1)
Aaron Mangold, MD (1) · Andrea Kneisel, MD (1) · Biagio Didona, MD (1) · Craig A Elmets (1) · Dagmar Simon (1) · Detlef Zillikens, MD (1) · Johannes Kern, MD (1) · Passeron Thierry, PhD (1) · Pier Adelchi Ruffini, MD (1) · Russell Hall, III, MD (1)
PMID 18087004, PMID 35507334, PMID 38443648, PMID 38508975, PMID 39310808
2019 (1)